Bio-Rad Laboratories, Inc. (BIO)
$
259.88
+6.81 (2.62%)
Key metrics
Financial statements
Free cash flow per share
11.8852
Market cap
7.1 Billion
Price to sales ratio
2.7818
Debt to equity
0.2050
Current ratio
0.0060
Income quality
-0.2381
Average inventory
380.4 Million
ROE
-0.3239
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Bio-Rad Laboratories, Inc. manufactures and distributes a comprehensive array of life science research and clinical diagnostic products across various regions, including the United States, Europe, Asia, Canada, and Latin America. Operating through its Life Science and Clinical Diagnostics segments, the Life Science segment is dedicated to the development, manufacturing, and marketing of reagents, apparatus, and laboratory instruments utilized in diverse research techniques, biopharmaceutical production processes, and food testing regimes. It strategically focuses on selected areas within the life sciences market, such as proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves a wide range of clients, including universities, medical schools, industrial research organizations, governmental agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. On the other hand, the Clinical Diagnostics segment specializes in designing, manufacturing, and supporting test systems, informatics systems, test kits, and specialized quality controls tailored for clinical laboratories within the diagnostics market. It offers reagents, instruments, and software that cater to specific niches in the in vitro diagnostics test market, selling these products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Additionally, the company provides products and systems aimed at separating complex chemical and biological materials, as well as identifying, analyzing, and purifying components. Bio-Rad Laboratories, Inc. utilizes a direct sales force supplemented by distributors, agents, brokers, and resellers to market its products. Established in 1952, the company is headquartered in Hercules, California. The net total of other income and expenses is -$2,611,500,000.00 reflecting non-core financial activities, while the cost of revenue for the company is $1,187,600,000.00 showcasing its production and operational expenses. Furthermore, the weighted average number of diluted shares outstanding is 28,214,000.00 reflecting potential dilution effects, and the weighted average number of shares outstanding is 28,214,000.00 highlighting the company's shareholder base. The EBITDA ratio is -0.82 underscoring the company's operational efficiency. Currently, the stock is priced at $259.88 positioning it in the higher-end market. However, it has a low average trading volume of 357,231.00 indicating lower market activity. With a mid-range market capitalization of $7,068,739,119.00 the company is viewed as a steady performer. Bio-Rad is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth through its advanced research and diagnostic solutions.
Is Bio-Rad Laboratories, Inc. (BIO) a good investment?
Investing in Bio-Rad Laboratories, Inc. (BIO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Bio-Rad Laboratories, Inc. (BIO)'s stock forecast?
Analysts predict Bio-Rad Laboratories, Inc. stock to fluctuate between $211.43 (low) and $387.99 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Bio-Rad Laboratories, Inc.'s market capitalization?
As of 2025-07-10, Bio-Rad Laboratories, Inc.'s market cap is $7,068,739,119, based on 27,200,012 outstanding shares.
How does Bio-Rad Laboratories, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Bio-Rad Laboratories, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Bio-Rad Laboratories, Inc. (BIO) stock?
To buy Bio-Rad Laboratories, Inc. (BIO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BIO. Place an order (Market, Limit, etc.).
What is the best time to invest in Bio-Rad Laboratories, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Bio-Rad Laboratories, Inc. stock ever split?
Bio-Rad Laboratories, Inc.'s last stock split was 2:1 on 2002-03-08.
How did Bio-Rad Laboratories, Inc. perform in the last earnings report?
Revenue: $2,566,500,000 | EPS: -$65.36 | Growth: 199.54%.
Where can I find Bio-Rad Laboratories, Inc.'s investor relations reports?
Visit https://www.bio-rad.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Bio-Rad Laboratories, Inc.?
You can explore historical data from here
What is the all-time high and low for Bio-Rad Laboratories, Inc. stock?
All-time high: $832.70 (2021-09-02) | All-time low: $211.43 (2025-06-03).
What are the key trends affecting Bio-Rad Laboratories, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
BIO, DECK and ELUXY have been added to the Zacks Rank #5 (Strong Sell) List on July 10, 2025.
globenewswire.com
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.
accessnewswire.com
SEATTLE, WA / ACCESS Newswire / June 13, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced that the Company is participating in the BIO International Convention occurring June 16-19, 2025, in Boston, MA. The conference is known for being the largest biotechnology industry conference of the year and is expected to attract more than 18,000 attendees from around the world.
globenewswire.com
PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate in the upcoming BIO 2025 International Conference, to be held in Boston, MA, June 16-19, 2025.
globenewswire.com
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that members of its executive team will attend the 2025 BIO International Convention, taking place June 16th – 19th in Boston, Massachusetts.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its participation in the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world's largest and most influential biotechnology event, c.
globenewswire.com
BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate overview at the upcoming 2025 BIO International Convention taking place in Boston, MA from June 16 – 19, 2025.
accessnewswire.com
Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its Chief Executive Officer and President and Chief Scientific Officer will be attending the BIO International Convention ("BIO") in Boston, June 16-19. With over 1,500 exhibitors and 20,000 attendees, BIO is the largest biotechnology convention in the world.
accessnewswire.com
Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026 MIAMI, FL / ACCESS Newswire / June 2, 2025 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced its participation in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has scheduled a full week of BIO One-on-One Partnering™ meetings to explore strategic collaborations, licensing opportunities, and potential M&A transactions.
globenewswire.com
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors
See all news
